The Immunology of Psoriasis-Current Concepts in Pathogenesis
Open accessThe DOI matches its Crossref record; 308 of the 308 references it cites were found in a registry or an index.
Abstract
Psoriasis is one of the most common inflammatory skin diseases with a chronic, relapsing-remitting course. The last decades of intense research uncovered a pathological network of interactions between immune cells and other types of cells in the pathogenesis of psoriasis. Emerging evidence indicates that dendritic cells, T H 17 cells, and keratinocytes constitute a pathogenic triad in psoriasis. Dendritic cells produce TNF-α and IL-23 to promote T cell differentiation toward T H 17 cells that produce key psoriatic cytokines IL-17, IFN-γ, and IL-22. Their activity results in skin inflammation and activation and hyperproliferation of keratinocytes. In addition, other cells and signaling pathways are implicated in the pathogenesis of psoriasis, including T H 9 cells, T H 22 cells, CD8 + cytotoxic cells, neutrophils, γδ T cells, and cytokines and chemokines secreted by them. New insights from high-throughput analysis of lesional skin identified novel signaling pathways and cell populations involved in the pathogenesis. These studies not only expanded our knowledge about the mechanisms of immune response and the pathogenesis of psoriasis but also resulted in a revolution in the clinical management of patients with psoriasis. Thus, understanding the mechanisms of immune response in psoriatic inflammation is crucial for further studies, the development of novel therapeutic strategies, and the clinical management of psoriasis patients. The aim of the review was to comprehensively present the dysregulation of immune response in psoriasis with an emphasis on recent findings. Here, we described the role of immune cells, including T cells, B cells, dendritic cells, neutrophils, monocytes, mast cells, and innate lymphoid cells (ILCs), as well as non-immune cells, including keratinocytes, fibroblasts, endothelial cells, and platelets in the initiation, development, and progression of psoriasis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The most frequent and important findings are represented by the psoriasiform pattern associated with confluent parakeratosis and chronic dermal inflammation.”
From The Cutaneous Immune Microenvironment in Selected Inflammatory Skin Diseases: Linking Histopathology, Mechanisms, and Targeted Therapy (2026) · cites this paper as [20]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Dilated and tortuous capillaries are frequently present in the papillary dermis and correspond clinically to the Auspitz phenomenon [20].”
From The Cutaneous Immune Microenvironment in Selected Inflammatory Skin Diseases: Linking Histopathology, Mechanisms, and Targeted Therapy (2026) · cites this paper as [20]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The disease is characterized by hyperproliferation of the epidermis, with a high epidermal turnover rate and scale formation.”
From The Cutaneous Immune Microenvironment in Selected Inflammatory Skin Diseases: Linking Histopathology, Mechanisms, and Targeted Therapy (2026) · cites this paper as [20]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Neutrophilic collections represent important diagnostic clues.”
From The Cutaneous Immune Microenvironment in Selected Inflammatory Skin Diseases: Linking Histopathology, Mechanisms, and Targeted Therapy (2026) · cites this paper as [20]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Fully developed plaques typically demonstrate regular acanthosis with elongated and relatively uniform rete ridges, thinning of the suprapapillary plates, confluent parakeratosis, and reduction or absence of the granular layer.”
From The Cutaneous Immune Microenvironment in Selected Inflammatory Skin Diseases: Linking Histopathology, Mechanisms, and Targeted Therapy (2026) · cites this paper as [20]
Experimental — accuracy not yet measured
13 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ivanov, I. I., McKenzie, B. S., Zhou, L., Tadokoro, C. E., Lepelley, A., Lafaille, J. J., Cua, D. J., & Littman, D. R. (2006) · Cell · doi:10.1016/j.cell.2006.07.035 · Cited by 5,145
A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17
Park, H., Li, Z., Yang, X. O., Chang, S. H., Nurieva, R., Wang, Y.-H., Wang, Y., Hood, L., Zhu, Z., Tian, Q., et al. (2005) · Nature Immunology · doi:10.1038/ni1261 · Cited by 4,265 · cited 2×
“However, IL-17 is also implicated in a variety of T H 17-mediated inflammatory autoimmune diseases [113, 114].”
BackgroundIL-23 drives a pathogenic T cell population that induces autoimmune inflammation
Langrish, C. L., Chen, Y., Blumenschein, W. M., Mattson, J., Basham, B., Sedgwick, J. D., McClanahan, T., Kastelein, R. A., & Cua, D. J. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20041257 · Cited by 4,099
Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review
Armstrong, A. W., & Read, C. (2020) · JAMA · doi:10.1001/jama.2020.4006 · Cited by 2,335
Liang, S. C., Tan, X.-Y., Luxenberg, D. P., Karim, R., Dunussi-Joannopoulos, K., Collins, M., & Fouser, L. A. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20061308 · Cited by 2,330 · cited 2×
“It was demonstrated that IL-17 and IL-22 can be co-expressed by T H 17 cells and synergize in the induction of the expression of AMPs by KCs in vitro [208].”
BackgroundPsoriasis Pathogenesis and Treatment
Rendon, A., & Schäkel, K. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20061475 · Cited by 2,064
Development, cytokine profile and function of human interleukin 17-producing helper T cells
Wilson, N. J., Boniface, K., Chan, J. R., McKenzie, B. S., Blumenschein, W. M., Mattson, J. D., Basham, B., Smith, K., Chen, T., Morel, F., et al. (2007) · Nature Immunology · doi:10.1038/ni1497 · Cited by 2,035
Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide
Lande, R., Gregorio, J., Facchinetti, V., Chatterjee, B., Wang, Y.-H., Homey, B., Cao, W., Wang, Y.-H., Su, B., Nestle, F. O., et al. (2007) · Nature · doi:10.1038/nature06116 · Cited by 1,910 · cited 3×
“Complexes consisting of DNA or RNA and LL37 are abundant in lesional skin [19, 106].”
BackgroundInterleukin-22, a TH17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis
Zheng, Y., Danilenko, D. M., Valdez, P., Kasman, I., Eastham-Anderson, J., Wu, J., & Ouyang, W. (2007) · Nature · doi:10.1038/nature05505 · Cited by 1,862 · cited 1×
“IL-22 produced by T H 22 cells mediates acanthosis and immune cell infiltration induced by IL-23 [69].”
BackgroundAggarwal, S., Ghilardi, N., Xie, M.-H., de Sauvage, F. J., & Gurney, A. L. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m207577200 · Cited by 1,847 · cited 3×
“T H 17 cells are activated by factors that are upregulated in the psoriatic milieu, including IL-23, as well as IL-21 in an autocrine manner [68, 74].”
Background
Cited by
Items 201–300 of 346
Psoriasis and risk of diabetic retinopathy in patients with type 2 diabetes mellitus
Yueh, M., Kao, S.-K., Chen, J., Huang, J., Chen, H.-S., & Wu, T.-E. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112912 · Cited by 2
Vaher, H. (2024) · British Journal of Dermatology · doi:10.1093/bjd/ljae223
The survival rate of biological therapy in immunosuppressive diseases in children
Радыгина, Т. В., Петричук, С. В., Fisenko, А. P., Купцова, Д. Г., Курбатова, О. В., Abdullaeva, L. М., Freidlin, E. V., Потапов, А. С., Murashkin, N. N., Kuzenkova, L. M., et al. (2024) · Russian Pediatric Journal · doi:10.46563/1560-9561-2024-27-5-322-330
Psoriasis vulgaris arising on a vascular malformation in an 11‐month‐old female child
Tartaglia, J., Franceschin, L., Tudurachi, I., Ciolfi, C., Caroppo, F., & Fortina, A. B. (2024) · Clinical Case Reports · doi:10.1002/ccr3.9209
Association of +67 G/A and -426 T/C Polymorphism in Eotaxin (CCL11) Gene with Psoriasis Phenotypes
Vašků, V., Fiala, A., & Vašků, A. (2025) · Genes · doi:10.3390/genes16030288
“In addition, other cells and signaling pathways are implicated in the pathogenesis of psoriasis, including T H 9 cells, T H 22 cells, CD8 + cytotoxic cells, neutrophils, γδ T cells, and cytokines and chemokines secreted by them [3].”
InfluentialMichelucci, A., Margiotta, F. M., Fanetti, F., Chittano, B., Fidanzi, C., Panduri, S., Morganti, R., Romanelli, M., & Dini, V. (2025) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2025.2480756
“By targeting IL 23, these therapies may more effectively disrupt the inflammatory pathway, resulting in more durable disease con-trol [35].”
Nakashima, Y., Gotoh, K., Yagi, M., Mizuguchi, S., Kang, D., Kanno, T., & Uchiumi, T. (2025) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2025.109922 · Cited by 1
Yang, K., Mircescu, A., Okusanya, D., Mohsen, S. T., Zeng, D., Czyz, S., Vallerand, I. A., Damiani, G. B., Bunick, C. G., & Jafarian, F. (2025) · medRxiv · doi:10.1101/2025.05.25.25328309
He, J., Feng, C., Xu, Y., Chen, S., Chen, J., Pan, J., Song, Y., Cheng, H., Zhu, J., & Zhu, J. (2025) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2025.5563 · Cited by 2
“DCs produce interleukin (IL)‑23, IL‑12, tumor necrosis factor‑ α (TNF‑ α ), and various other cytokines that signifi‑ cantly enhance the differentiation of naive T cells into Th (T help)1, Th17, and Th22 subsets.”
The role of fibroblasts in psoriasis pathogenesis
Yun, S., Park, J., & Nam, K. (2025) · Daehan geonseon hakoeji (Online) · doi:10.23203/jksp.2025.22.1.19
Tantipat, S., Trisuwan, K., Kunnaja, P., Sireeratawong, S., Natakankitkul, S., Imiam, S., & Chansakaow, S. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17070864
“IL-6 IL-6 in particular has emerged as both a biomarker for disease activity and a potential therapeutic target [16].”
Sun, N., Li, S., Liu, X., Li, Q., Chen, C., Wu, Z., Song, Y., Zhang, C., Zhu, J., & Zhu, J. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5323889
Sun, N., Li, S., Liu, X., Li, Q., Chen, C., Wu, Z., Song, Y., Zhang, C., Zhu, J., & Zhu, J. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5323905
Plasma proteomics-based risk scores for psoriasis prediction: a novel approach to early diagnosis
Wei, S., Yue, Z., Sun, C., Zou, Y., Chen, H., Tao, J., Xu, J., Xu, Y., Wang, N., Guo, Y. P., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1618805
“Psoriasis is a chronic, painful, and disabling non-communicable disease mediated by the immune system that manifests as red papules and plaques, usually covered with white or silvery scales (1, 2).”
Koycheva, I. K., Stoyanova, E., Todorova, B., Stoykova, I. D., Savova, M. S., Mihaylova, L. V., Mihaylova, N., & Georgiev, M. I. (2025) · South African Journal of Botany · doi:10.1016/j.sajb.2025.07.005
Cui, M., Wang, S., Yang, F., Wang, Y., Kong, F., Kong, N., Li, M., Qiao, X., Xu, Z., Yan, Z., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.07.21.665890
TCN2 promotes psoriatic skin inflammation and keratinocyte proliferation via the IL-1β-STAT3 pathwayPreprint
Xu, J., Zhou, X.-Z., Xue, K., Li, A., Xia, Q., Zhou, Z., Song, X., Zuo, X.-B., & Cui, Y. (2025) · Research Square · doi:10.21203/rs.3.rs-7309098/v1
Network pharmacology and Mendelian randomization analysis of Xiao Bi decoction in treating psoriasis
Hu, W., Jiang, Y., Wang, J., Jia, M., Chun-lan, W., & Wen, C. (2025) · Medicine · doi:10.1097/md.0000000000044173
“[40] TNF inhibitors such as infliximab, adalimumab, and etanercept are the preferred biologics for the treatment of moderate to severe psoriasis.”
Stopyra, M., Feret, K., Andrzejczyk, A., Nafalska, N., Tomaszewska, A., Gadzinowska, J., Kokoszka, M., Chodór, M., Szpila, G., & Lewandowska, A. (2025) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.3(47).2025.3970
Mindfulness and the Mediterranean diet as alternative therapies in ambulatory care of psoriasis
Barrios, X. L., Carreón‐Torres, E., & Estrada-Luna, D. (2025) · International Journal of Research in Dermatology · doi:10.18203/issn.2455-4529.intjresdermatol20253404
Treating steroid-dependent psoriasis from the blood-heat syndrome perspective: A case report
Jiang, M.-Y., & Jiang, Y. (2025) · Medicine · doi:10.1097/md.0000000000045926
“[9,10] Conventional first-line therapies (corticosteroids, vitamin D analogs, and biologics) [11] exhibit critical limitations: corticosteroid dependence/atrophy, [7] hypercalcemia risk from vitamin D analogs, and infection/cost burdens with biologics.”
Salivary Immune and Endocrine Biomarkers in Skin and Mucocutaneous Diseases
Špiljak, B., Dolački, L., Parać, E., & Lugović‐Mihić, L. (2025) · Advances in experimental medicine and biology · doi:10.1007/978-3-032-03176-1_12 · Cited by 1
BIOLOGICAL TREATMENT OF PSORIASIS – MECHANISMS OF ACTION, CLINICAL EFFICACY AND SAFETY OF THERAPY
Piskorz, P., Sobota, W., Biesaga, P., Jadanowski, O., Łebek, K., Bury, A., Litworska-Sójka, D., Komsta, B., Lipiec, J., & Pabis, W. (2025) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.4(48).2025.4043
Qin, G., Wu, Z., Li, Y., Jia, M., Wang, Y., Sun, X., Huang, X. F., Huang, T., & Zhong, J. (2025) · Microbiology and Immunology · doi:10.1111/1348-0421.70032
Rizzo, D., Licata, G., Frazzitta, M., & Zichichi, L. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14248875
“Most commonly, psoriasis presents as plaque psoriasis (psoriasis vulgaris), occurring in 80% of cases [5,6].”
InfluentialKong, Y., Li, X., Yang, F., Wang, J., Guo, P., Ren, C., Duan, Z., Bi, M., Wang, Y., Liu, F., et al. (2025) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2025.153143
Advancing Psoriasis Care: Efficacy of Nanosuspensions in Targeted Skin Therapies
Parihar, A., Paliwal, H., Kaur, J., Pal, S., Prajapati, B., & Sharma, R. (2025) · Biomedical Materials & Devices · doi:10.1007/s44174-025-00590-0
Zhang, S., Jiang, T., Sun, H., Yang, D., Cao, L., Li, M., Xu, A., Gu, Q., Wu, W., Li, Y., et al. (2025) · Chemical Engineering Journal · doi:10.1016/j.cej.2025.171970
Wei, Y., Liu, M., Mou, K., Wang, L., & Zheng, Y. (2025) · Clinical Cosmetic and Investigational Dermatology · doi:10.2147/ccid.s557553
Plant Secondary Metabolites: Therapeutic Potential and Pharmacological Properties in Psoriasis
Kaur, S., Arora, A., Paul, T. J., Singh, D., & Singh, A. (2025) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9798898812799125010004
Kaya, Ö., Şehitoğlu, M. H., MERMUTLU, S. I., Kiliç, S. O., & Hakkı, K. A. Y. A. (2026) · Archives of Dermatological Research · doi:10.1007/s00403-025-04492-5
“The roles of TLRs, integrins, IGFs, and latent TGFβ in the pathogenesis of psoriasis are well established [1, 32, 33].”
Evaluation of Major Autohemotherapy (MAH) in Psoriasis Patients Using Serum Inflammatory Markers
Soylu, S., Şensoy, N., DOĞAN, N., Koca, H. B., & Köken, T. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15020485
Khunt, C. R., & Jani, D. K. (2026) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-025-04965-4
Hu, J., Tang, M. X., Zheng, Q., Liang, S., Xu, G., & Zhang, K.-Q. (2026) · Scientific Reports · doi:10.1038/s41598-026-37417-x
“These pathways are well-established drivers of keratinocyte hyperproliferation and immune cell activation in the pathogenesis of psoriasis 2,28 .”
Liu, G., Gong, F., Yang, G., & Luo, Q. (2026) · Clinical Cosmetic and Investigational Dermatology · doi:10.2147/ccid.s578871
Xu, Z., Li, Z., Qu, J., Liang, C., Zhang, Y., Zhao, Q., & Li, Q. (2026) · Pharmaceuticals · doi:10.3390/ph19020236 · Cited by 1
Li, C., Tsai, C.-I., & Yu, S. (2026) · 童綜合醫學雜誌 · doi:10.4103/etmj.etmj-d-25-00044
Body composition changes in musculoskeletal diseases
Gizatullina, R. R., Gafuryanova, E. M., Latypova, L. A., & Tyurin, A. V. (2026) · Modern Rheumatology Journal · doi:10.14412/1996-7012-2026-1-119-124 · Cited by 1
Bae, Y. J., Go, T. H., Hương, N. T. T., Hân, L. N., & Hwang, H. S. (2026) · Journal of Applied Biological Chemistry · doi:10.3839/jabc.2026.009
Immunomodulatory Effects of a Tick Salivary Serpin on Psoriasis-like Inflammation
Jmel, M. A., Wu, H., Baaten, C. C. F. M. J., Xu, X., Nandakumar, K. S., & Kotsyfakis, M. (2026) · Life · doi:10.3390/life16030427
“IL-23 is primarily produced by myeloid immune cells such as dendritic cells, which plays a pivotal role in disease progression by driving the IL-17/IL-22 pathway and directly inducing epidermal hyperplasia in psoriasis [52,53].”
P300 in Inflammation: An Updated Perspective on Its Molecular Mechanisms and Therapeutic Potential
Zhang, N., Cao, L., Han, D., Zhou, K., Liao, Z., Du, J., Li, H., Zhou, J., Liu, J., & Tu, J. (2026) · Inflammation · doi:10.1007/s10753-025-02441-y · Cited by 1
“These cytokines work together to cause excessive proliferation of skin keratinocytes and infiltration of inflammatory cells, resulting in characteristic erythema and psoriasis plaques [59].”
Zhang, Q., Gao, Y., Feng, C., Yang, L., Chen, F., Guo, S. S., Liu, Y., Lu, Q., Ji, C., & Shen, H. (2026) · Mediators of Inflammation · doi:10.1155/mi/9564209
“Within the intricate in fl ammatory network characteristic of psoriasis, KCs are generally recognized to occupy a central and pivotal position [59].”
Zhou, Q., Wang, Z., Wang, Y., Guan, J., He, L., Yang, J., Chi, Y., Zhao, L., Zhang, B., Zeng, K., et al. (2026) · Acta Materia Medica · doi:10.15212/amm-2025-0058
Mao, Y., Shi, J., Zhu, W., Ling, G., & Zhang, P. (2026) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2026.151554
THE ROLE OF GLP-1 RECEPTOR AGONISTS IN THE TREATMENT OF PSORIASIS: A POTENTIAL THERAPEUTIC APPROACH
Majda, A., Pająk, J., Kucharski, K., Kamosińska, A., & Kowal, A. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.1(49).2026.5073
“Psoriasis is a chronic, recurrent, inflammatory skin disease affecting approximately 125 million people worldwide, with a prevalence ranging from 0.1% to 8% depending on geographic region [1,2].”
InfluentialQiao, Z.-Y., Liu, J., Luo, N., Tang, L., Ma, W., Cheng, Z.-L., & Hao, P. (2026) · Clinical Cosmetic and Investigational Dermatology · doi:10.2147/ccid.s594617 · Cited by 1
Waheed, G., Ramadan, G., & Mohammed, H. A. (2026) · International Immunopharmacology · doi:10.1016/j.intimp.2026.116580
Cortés-Ruiz, M. G., Hidalgo, K. A. W., Hernandez-Nicols, B. F., Buenrostro-Camacho, F. G., Hernández‐Bello, J., Graciano‐Machuca, O., & Alvarado‐Navarro, A. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27073202
“The pathogenesis of psoriasis is complex and involves multiple immunological, ge-netic, and environmental factors [6] which initiate the inflammatory signaling cascade, leading to alterations in keratinocyte differentiation and a chronic inflammatory process.”
Ruggiero, A., Burlando, M., Balato, A., Narcisi, A., Galluzzo, M., Mastorino, L., Brizzi, E. V. D., Campione, E., Gargiulo, L., Cozzani, E., et al. (2026) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2026.2641059
“IL-17 and IL-23 in particular are recognized as key drivers of the disease [1,5,6].”
Xie, M., Ma, X., Zhang, Y., Kuai, L., Luo, Y., Song, J., Ding, X., Ru, Y., Luo, Y., Fei, X., et al. (2026) · Biomedicines · doi:10.3390/biomedicines14040804
“Recent single-cell studies have refined the cellular architecture of psoriasis and identified pathogenic dendritic cells (DC) and T-cell states [6,11,12], including inflammatory myeloid subsets that sustain IL-23 production and effector populations such as IL-17-producing CD8 + T cells (Tc17) cells…”
IFN-I Induces Keratinocytes Necroptosis via ZBP1-MLKL Axis in Oral Lichen Planus
Jiang, X., Chen, J., Yao, Y., Lai, Y., Yang, X., Deng, Y., Tang, G., Sun, L., & Wang, Y. (2026) · Inflammation · doi:10.1007/s10753-026-02497-4
Wang, J., Zhou, Z. C., Chen, Y., Li, Q., Zhai, L., Li, D., Qin, S., & He, Y. (2026) · Biology Direct · doi:10.1186/s13062-026-00734-2
“They are critically involved in both initiation and perpetuation of psoriasis, regulating innate immune response through the secretion of immunomodulatory molecules and promoting the activation of infiltrating immune cells [20].”
Wang, Y., Zeng, W., Zhang, F., Li, J., Zeng, W., Bai, Y., & Li, C. (2026) · Combinatorial Chemistry & High Throughput Screening · doi:10.2174/0113862073452423260117194932
Redko, S. R., & Руднева, Н. С. (2026) · Medical alphabet · doi:10.33667/2078-5631-2026-3-18-23
Pre‐existing psoriasis and immune‐related adverse events following immunotherapy for lung cancer
Corey, S., Braun, N., Thompson, B. B., Lin, C., REYNOLDS, K. L., Sheng‐Kai, K., & Chen, S. T. (2026) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.70452
Tumor necrosis factor inhibitors
Tregubchak, T. V., & Shchelkunov, S. N. (2026) · Acta Naturae · doi:10.32607/actanaturae.27697
A Novel Chronic Psoriasis Mouse Model via Optimized Imiquimod Dosing and Machine Learning Evaluation
Zhu, H., Yu, X., Wang, Y., Zhao, N., Qu, B., Ma, H., Meng, Y., Zhao, J., Yan, W., & Li, P. (2026) · Journal of Inflammation Research · doi:10.2147/jir.s590945
“…only the D-D model exhibited Intermediate levels of IL-17A, IL-22, and IL-23—all three major mediators of psoriasis— compared with all other models 29,30 (Figure 3i–k), unlike high IMQ frequency administration where peak levels of inflammatory factor expression usually reached a high state, the…”
Zhang, H., Yang, R., Ma, Y., Yang, J., Yang, B., Dong, L., & Yu, N. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1806248 · Cited by 2
“This involves the activation of T cells, particularly Th1/Th17 cells, whose release of multiple cytokines — such as IL-17A, TNF-a , IFN-g , and IL-22 — serves as key drivers of the local in fl ammatory response in PSO (4).”
An intelligent framework for advancing large-scale omics data integration
Cui, M., Wang, S., Yang, F., Wang, Y., Kong, F., Kong, N., Li, M., Qiao, X., Xu, Z., Yan, Z., et al. (2026) · iScience · doi:10.1016/j.isci.2026.115928
“35 Patients often experience recurrence after the cessation of treatment.”
Çelik, M. S., Asır, F., Aktaş, H., Çetin, A., Celik, C., Cepik, N., Acar, G. E. A., & Türe, Z. (2026) · Cutaneous and Ocular Toxicology · doi:10.1080/15569527.2026.2671007
“…TFR2 expression in inflammatory areas suggests a potential role for TFR2 in iron-related pathways involved in the pathophysiology of PV. Psoriasis vulgaris (PV) is a chronic inflammatory skin disease characterized by immune dysregulation, keratinocyte proliferation, and epidermal hyperplasia [1].”
Liu, J., Zhang, Z., & Liu, T. (2026) · Journal of International Medical Research · doi:10.1177/03000605261447159
“15 As observed in the present case, recurrent lesions involving the head and neck are often particularly difficult to control.”
Kerry, R. G., Ray, A., Panda, P. C., Nayak, V., Patra, S., Pandey, R., MOHANTY, B. S., Dutta, A., Maurya, G. K., Rout, J. R., et al. (2026) · Archives of Dermatological Research · doi:10.1007/s00403-026-04614-7 · Cited by 1
“…element of skin immunity, antigen-experienced memory T cells amounts to ~ 20 billion in healthy adult skin (as per Clark et al., [58] there are ∼ 1 × 10 6 T cells/cm 2 normal skin and an estimated 2 × 10 10 T cells in the entire skin), whereas in psoriatic lesions it is 100 times higher [15, 59].”
InfluentialWaheed, G., Mohammed, H. A., & Ramadan, G. (2026) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-026-05431-5
“Additionally, accumulating evidence indicated that mast cells are capable of synthesizing IL-17A, especially in response to IL-23, and may support the survival of Th17 lymphocytes (Sieminska et al. 2024).”
InfluentialYe, Z., Gao, B., Huijing, T., & Zhu, L. (2026) · Gene · doi:10.1016/j.gene.2026.150225
Baena, A. M. V., Rueda, J. P., Piedrahita, D. C., González-Rodríguez, G., & Burbano, J. C. (2026) · Revista Hispano-Americana de Dermatología Pediátrica · doi:10.29176/30284163.2313
Zhang, N., Li, Y., Zhang, W., Wu, Q., Wang, M., Liu, X., Shi, R., & li, S. (2026) · Biochemical Pharmacology · doi:10.1016/j.bcp.2026.118097
Kemeness, C., García-Hernández, M. D. L. L., Schandua, H., Gupta, R., Spangenberg, A., Ritchlin, C. T., & Liao, W. J. (2026) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2026.102165
Yu, W., Qi, B., Cong, C., Ma, Y., Kong, Q., & Sang, H. (2026) · Journal of Molecular Histology · doi:10.1007/s10735-026-10816-0
“It is generally believed that an abnormal immune microenvironment, was a key pathogenic factor in the development of psoriasis, such as abnormal secretion of pro-inflammatory cytokines and chemokines (Sieminska et al. 2024; Mabuchi et al. 2012; Xu et al. 2013 ).”
Zhang, R., Wang, X., Dong, M., Tan, Q., Wang, A., Zhu, T., Gu, Z., Xia, J., & Wang, J. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.115054
Wang, W., Zha, S.-Y., Sun, L., & Zhou, D. (2026) · Psoriasis Targets and Therapy · doi:10.2147/ptt.s604199
“11 In older patients, age-related changes in both innate and adaptive immunity may further shape these processes and may help explain persistent inflammation, differences in clinical presentation, and possible variation in response to biologic therapy.”
InfluentialLanbing, D., Yang, Z., Wang, Z., Zeng, B., Peng, M., Min, W., & Zhou, Y. (2026) · Pathology - Research and Practice · doi:10.1016/j.prp.2026.156577
Joshi, R., & Brijesh, S. (2026) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2026.108566
Bobde, M., Purohit, A., Nema, P., Sahu, A., Kashaw, V., Soni, V., & Kashaw, S. K. (2026) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2026.127049 · Cited by 2
Pujari, P. B., Shedmake, A. C., Shinde, A. J., Mali, S. S., Husukale, P. S., Chidrawar, V. R., Nagime, P. V., Patil, P. B., Shafi, S., & Singh, S. K. (2026) · Next research. · doi:10.1016/j.nexres.2026.102005
Kujach, A., & Góralska, J. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.2(50).2026.5305
CURE: a phase-based therapeutic framework for chronic inflammation
Kurzen, N., Weißinger, S., & Kurzen, H. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1826568
Keratinocytes, neutrophils, IL-17 – the “three pillars” of psoriatic inflammation
Анатольевна, М. Е., Shishkova, Y. S., & Nefedyeva, Y. V. (2026) · Medical Immunology (Russia) · doi:10.15789/1563-0625-kni-3357
Liu, J., Shao, J., Hou, L., Mei, E., He, L., Wang, J., Chen, A., Zhang, Y., & Li, Z. (2026) · Journal of Dermatological Treatment · doi:10.1080/09546634.2026.2641340
Shared inflammatory architecture and therapeutic tensions between psoriasis and Crohn’s disease
Wang, X., Li, J., Yu, K., Wu, X., & Luo, Q. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1871406
“In psoriasis, IL-23-driven type 17 responses promote IL-17-and IL-22-mediated keratinocyte activation, chemokine production, antimicrobial peptide release, neutrophil recruitment, and epidermal hyperplasia (21, 30).”
InfluentialBondare-Ansberga, V., Tretjakovs, P., Svirskis, Š., Jurka, A., Miķelsone, I., Limba, N., Blumfelds, L., & Hartmane, I. (2026) · Research Square · doi:10.21203/rs.3.rs-9871454/v1
Yi, Q., Chen, X., & Zhang, L. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1876454
“Therefore, no causal inference can be drawn from the present case (16, 17).”
Zhang, Y., Shi, Z., Mo, X., Ju, Q., & 潘展砚 (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1853603 · Cited by 1
“By modulating the activity of in fl ammatory transcription factors, it balances pro-in fl ammatorymediators(e.g.,TNF-a ,IL-1 b )againstanti-in fl ammatory factors (e.g., IL-10), potentially in fl uencing cutaneous in fl amma-tory responses.”
Xu, J., Zhou, X., Xue, K., Li, A. L., Xia, Q., Zhuang, Z., Song, X., Zuo, X.-B., & Cui, Y. (2026) · The FASEB Journal · doi:10.1096/fj.202600470r
“These studies have provided not only a solid theoretical foundation for clinical management but also essential guidance for the development of targeted therapies [19–21].”
Liu, R., Wu, Y., Jia, W., Wang, E., Zheng, S. J., & 阮庆国 (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1849308
Jaungo-based herbal complex regulates psoriasis-associated macrophage–keratinocyte inflammatory axis
Byeon, J.-A., Ye, S., Seo, E.-B., & Kwon, Y. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1819017
Chakith, M. R. S., Pradeep, S., Raj, R., Reddy, P., Kolachi, K. Y., Dharmashekara, C., Maheshwari, N. C., Kollur, S. P., Abass, K. S., Stupin, V., et al. (2026) · Scientific Reports · doi:10.1038/s41598-026-47049-w
“They were ideal subjects for research on drug-cytokine interactions because of their involvement in skin disorders and systemic inflammation 16 .”
ÖDEMİŞ, H., Kuru, B. C., Doğan, B., Kuş, C. C., Celik, M., Kızıltoprak, N., & Özçelik, F. (2026) · JEADV Clinical Practice · doi:10.1002/jvc2.70400
Chen, L., Qiao, Z.-Z., Xu, C., Yao, Y., Yang, Y.-Y., Zhang, X.-Y., Cheng, S.-F., Zhang, B., & Yang, X.-Y. (2026) · Frontiers in Physiology · doi:10.3389/fphys.2026.1884398
CEACAM5 drives psoriatic inflammation by regulating CD8+ T cell recruitment and activation
Wang, L., Liu, X., Cao, K., Liu, Y., Liang, S., Xu, L., & Xu, Z. (2026) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2026.102695
“[ 15 – 18].”
InfluentialOsterhus, V., Böhm, M., & Koenig, S. (2026) · Current Medical Science · doi:10.1007/s11596-026-00232-6
“Psoriasis patients exhibit an overactive immune response with heterogeneous clinical features, including cutaneous and systemic manifestations [18].”
Zhang, L., Qi, X., Ma, B., Jin, R., Shao, Y., & Gao, Y. (2026) · RSC Advances · doi:10.1039/d6ra03228a
Jl, P., Xu, Y., Chen, Y., Zhu, J. F., Song, Y., & Cheng, H. (2026) · International Immunopharmacology · doi:10.1016/j.intimp.2026.117164
A programmable nanoplatform for inflammatory-state reprogramming in psoriasis treatment
Chen, Z., Zhao, J., Huang, S., Lou, G., Jin, M., Nan, Z., Gao, Z., Wang, S., & Jin, J. (2026) · Journal of Nanobiotechnology · doi:10.1186/s12951-026-04842-z
“…of keratinocytes, amplification of the immune-inflammatory axis centered on IL-17 A, oxidative stress, mitochondrial dysfunction, and skin barrier disruption interact with dysbiosis to lock the local inflammatory state, leading to the recurrence and difficulty in curing psoriasis [4, 5].”
Lymperi, A., Lamprianidou, E., Adamantidi, T., Chatzikamari, M., Loizidis, N., Dania, V., & Τσούπρας, Α. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27156780
Jin, M., Li, Y., Kong, Y., Cheng, X., & Zhang, J. (2026) · Clinical Immunology · doi:10.1016/j.clim.2026.110753
Cheng, H., Pan, Y., Xu, X., Chen, Y., Chen, J., Bi, K., & Liu, S. (2026) · International Journal of Clinical Practice · doi:10.1155/ijcp/7176105
Jin, S., Chen, J., He, Y., Guo, Y., Zhang, J., Zhang, Z., Ye, F., & Chen, G. (2026) · Fitoterapia · doi:10.1016/j.fitote.2026.107422
Evaluating zasocitinib as an oral therapy for moderate to severe plaque psoriasis
McGuirt, V., Razler, D., Moore, S. G., & Feldman, S. R. (2026) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2026.2714835
“● Zasocitinib has the potential to reshape psoriasis treatment strategies, depending on its safety. phase [26,27].”
PSORÍASE: UMA REVISÃO SOBRE EPIDEMIOLOGIA, FISIOPATOLOGIA, MANIFESTAÇÕES CLÍNICAS E TRATAMENTO
Bichara, B. D. A. E. S., Silva, C. A., Scaramussa, L. P., & Pereira, J. D. O. (2026) · International Journal of Health Management Review · doi:10.47172/ijhmreview.v12i3.577
Wang, S., Zhang, Z., Han, L., Yan, K., & Xu, J. (2026) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-026-05730-x
Metadata
- Authors
- Sieminska, I., Pieniawska, M., & Grzywa, T. M.
- Affiliations
- Institute of Human Genetics (PL)
- Children's Hospital of Philadelphia (US)
- Corresponding author
- Grzywa, Tomasz M.
- Venue
- Clinical Reviews in Allergy & Immunology
- Published
- 2024-04-20
- Volume
- 66
- Issue
- 2
- Pages
- 164-191
- ISSN
- 1080-0549 (ISSN-L)
- 1559-0267
- PMC
- PMC11193704
- OpenAlex
- W4394989398
- Semantic Scholar
- 7834ce05fae760dae63e391276786d133a044e08
- Cited by
- 346
- References
- 308
- Citations by year
- 2026: 187 · 2025: 140 · 2024: 19
- FWCI
- 15.26
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Clinical Reviews in Allergy & Immunology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Narodowe Centrum Nauki (2021/41/N/NZ6/02774)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
- Health Sciences › Medicine › Dermatology › Dermatology and Skin Diseases
- Health Sciences › Medicine › Rheumatology › Spondyloarthritis Studies and Treatments
- Keywords
- psoriasis, psoriasis pathogenesis, dendritic cells, Th17 cells, keratinocytes, IL-23, TNF-α, IL-17, IL-22, Th9 cells, Th22 cells, cytotoxic T lymphocytes, neutrophils, γδ T cells, innate lymphoid cells, mast cells, non-immune cells, skin inflammation, immune dysregulation
- MeSH terms
- Animals, Dendritic Cells, Humans, Psoriasis, Skin, Signal Transduction, Keratinocytes, T-Lymphocyte Subsets, Cytokines, Th17 Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.